61-75 of 301
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart MattersTreating ATTR-CM Early: A Shift From Reactive to Strategic Care
Quan Bui, MD
Recognizing Methamphetamine-Associated PAH: Strategies for Complex Care
Deep Breaths: Updates from CHESTRecognizing Methamphetamine-Associated PAH: Strategies for Complex Care
Rodolfo A. Estrada MD, FCCP
Steven M. Hollenberg, MD
Dana Kay, DO
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart MattersAdvancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstractsExploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Hallie Blevins, PhD
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart MattersUnderstanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart MattersATTR-CM Trials Revisited: A Broader View of Treatment Benefit
- advertisement
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstractsFrom HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
Hallie Blevins, PhD
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
AudioAbstractsManaging Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
Marlene Mimi Maeusli, PhD.
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Ryan Quigley
Kathrin M. Bernt, MD
Rushabh Mehta, BS
Fatemeh Alikarami
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
- advertisement
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP
Luhua (Michael) Wang, MD
